Filing Details

Accession Number:
0001104659-19-068763
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-02 07:20:03
Reporting Period:
2019-11-27
Accepted Time:
2019-12-02 07:20:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1279695 Universal Biosensors Inc UBI Surgical & Medical Instruments & Apparatus (3841) 980424072
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1678533 E. Craig Coleman 1 Corporate Avenue
Victoria C3 3178
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-11-27 214,783 $0.19 34,631,325 No 4 P Indirect By Partnership
Common Stock Acquisiton 2019-11-28 1,885,217 $0.20 36,516,542 No 4 P Indirect By Partnership
Common Stock Acquisiton 2019-12-02 119,519 $0.20 36,636,061 No 4 P Indirect By Partnership
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Partnership
No 4 P Indirect By Partnership
No 4 P Indirect By Partnership
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 220,000 Indirect By the Coleman Super Fund
Footnotes
  1. Traded as Chess Depository Interests ("CDIs") on the Australian Stock Exchange. CDIs represent beneficial interests in the common stock held by CHESS Depository Nominees Pty Ltd.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.190 to $0.195. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.190 to $0.200. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $0.200. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  5. The price per share of the common stock reported is stated in Australian dollars, as converted from a U.S. dollar price on the date of the transaction.
  6. The Reporting Person is a director of Viburnum Funds Pty Ltd ("Viburnum"), which is the manager of each of VF Strategic Equities Fund ("Strategic Fund"), VF High Conviction Fund ("Conviction Fund"), and separately managed accounts on behalf of a Viburnum client ("Strategic Mandates") the direct beneficial owners of the common stock. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the common stock held by Strategic Fund, Conviction Fund, and Strategic Mandates, except to the extent of his pecuniary interest therein.
  7. Viburnum, as the manager of Strategic Fund, Conviction Fund and Strategic Mandates, may be deemed to beneficially own 36,636,061 shares of common stock, which consists of 18,442,469 and 11,828,110 and 6,365,482 shares of common stock held by Strategic Fund and Conviction Fund and Strategic Mandates, respectively. Viburnum, as the manager of each of Strategic Fund, Conviction Fund and Strategic Mandates, shares voting and dispositive power over, and may be deemed to beneficially own, the common stock held by the foregoing entities. The Reporting Person shares voting and dispositive power over, and may be deemed to beneficially own, the common stock held by the foregoing entities due to the Reporting Person serving as a director of Viburnum.
  8. Craig E. and Phylis Coleman are the trustees of the Coleman Super Fund, of which Mr. Coleman is a potential beneficiary.